Immuneering Co. (NASDAQ:IMRX) Short Interest Up 6.3% in June

Immuneering Co. (NASDAQ:IMRXGet Free Report) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totalling 3,690,000 shares, an increase of 6.3% from the May 31st total of 3,470,000 shares. Approximately 17.6% of the company’s shares are short sold. Based on an average daily trading volume, of 376,900 shares, the days-to-cover ratio is presently 9.8 days.

Analyst Upgrades and Downgrades

IMRX has been the topic of a number of analyst reports. Mizuho reduced their price objective on Immuneering from $20.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Jefferies Financial Group reissued a “hold” rating and set a $3.00 target price (down previously from $16.00) on shares of Immuneering in a research note on Friday, March 15th. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of Immuneering in a research note on Wednesday, May 8th. TD Cowen reissued a “market perform” rating on shares of Immuneering in a research note on Friday, March 15th. Finally, Chardan Capital cut their target price on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, March 15th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

View Our Latest Stock Report on IMRX

Institutional Investors Weigh In On Immuneering

A number of institutional investors have recently modified their holdings of IMRX. Exchange Traded Concepts LLC grew its stake in Immuneering by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 17,416 shares of the company’s stock worth $128,000 after purchasing an additional 4,417 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in Immuneering during the 3rd quarter worth $154,000. Adage Capital Partners GP L.L.C. grew its stake in Immuneering by 11.4% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 195,000 shares of the company’s stock worth $1,498,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Immuneering by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after purchasing an additional 129,851 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Trading Up 3.7 %

Shares of NASDAQ IMRX opened at $1.13 on Friday. Immuneering has a twelve month low of $1.05 and a twelve month high of $11.06. The stock has a fifty day simple moving average of $1.46 and a 200-day simple moving average of $3.82. The stock has a market capitalization of $33.50 million, a PE ratio of -0.60 and a beta of -0.61.

Immuneering (NASDAQ:IMRXGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). On average, equities analysts predict that Immuneering will post -1.93 earnings per share for the current year.

About Immuneering

(Get Free Report)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

Read More

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.